| Literature DB >> 34552866 |
Jieyi Long1, Tingting Long1, Ying Li1, Peihong Yuan1, Ke Liu1, Jiaoyuan Li1, Liming Cheng1.
Abstract
BACKGROUND: The disease-associated non-coding variants identified by genome-wide association studies (GWASs) were enriched in open chromatin regions (OCRs) and implicated in gene regulation. Genetic variants in OCRs thus may exert regulatory functions and contribute to non-small cell lung cancer (NSCLC) susceptibility.Entities:
Keywords: chromatin accessibility; heterochromatin protein 1 gamma; non-small cell lung cancer; single-nucleotide polymorphism; susceptibility
Year: 2021 PMID: 34552866 PMCID: PMC8450516 DOI: 10.3389/fonc.2021.698993
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Characteristics of subjects in the two-stage case–control study.
| Stage 1 | Stage 2 | Combined population | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case | Control | χ2 |
| Case | Control | χ2 |
| Case | Control | χ2 |
| |
| Total | 348 | 479 | 1,482 | 1,522 | 1,830 | 2,001 | ||||||
| Age (mean ± SD) | 56.3 ± 7.8 | 55.2 ± 9.7 | 0.083 | 55.1 ± 8.7 | 54.9 ± 8.1 | 0.652 | 55.3 ± 8.6 | 55.0 ± 8.5 | 0.281 | |||
| Sex, n (%) | ||||||||||||
| Male | 196 (56.3) | 270 (56.4) | 0.0 | 0.990 | 967 (65.2) | 1,006 (66.1) | 0.24 | 0.625 | 1,163 (63.6) | 1,276 (63.8) | 0.02 | 0.889 |
| Female | 152 (43.7) | 209 (43.6) | 515 (34.8) | 516 (33.9) | 667 (36.4) | 725 (36.2) | ||||||
| Smoking status, n (%) | ||||||||||||
| Smoker | 145 (41.7) | 160 (33.4) | 5.91 | 0.052 | 736 (49.7) | 628 (41.3) | 23.80 | <0.001 | 881 (48.1) | 788 (39.4) | 30.96 | <0.001 |
| Non-smoker | 198 (56.9) | 311 (64.9) | 734 (49.5) | 887 (58.3) | 932 (50.9) | 1,198 (59.9) | ||||||
| Unknown | 5 (1.4) | 8 (1.7) | 12 (0.8) | 7 (0.5) | 17 (0.9) | 15 (0.7) | ||||||
| Histology, n (%) | ||||||||||||
| Adenocarcinoma | 256 (73.6) | 936 (63.2) | 1,192 (65.1) | |||||||||
| Squamous cell carcinoma | 76 (21.8) | 415 (28.0) | 491 (26.8) | |||||||||
| Other | 16 (4.6) | 131 (8.9) | 147 (8.0) | |||||||||
Results of association analyses between individual SNPs and NSCLC risk in stage 1.
| rs ID |
| MAF |
|
| OR (95%CI) |
| |
|---|---|---|---|---|---|---|---|
| Case | Control | ||||||
| rs13064999 | 0.922 | 0.41 | 0.37 | 3.19 | 0.074 | 1.21 (0.98–1.48) | 0.072 |
| rs62290287 | 0.516 | 0.45 | 0.45 | 0.02 | 0.881 | 0.98 (0.80–1.19) | 0.814 |
| rs71317943 | 0.729 | 0.26 | 0.27 | 0.12 | 0.727 | 0.98 (0.77–1.23) | 0.886 |
| rs4946258 | 0.515 | 0.42 | 0.45 | 1.50 | 0.221 | 0.89 (0.72–1.09) | 0.244 |
| rs11169971 | 0.542 | 0.35 | 0.34 | 0.04 | 0.835 | 1.02 (0.83–1.25) | 0.880 |
| rs8079078 | 0.072 | 0.20 | 0.20 | 0.05 | 0.828 | 1.02 (0.78–1.33) | 0.902 |
| rs34122828 | 0.892 | 0.18 | 0.21 | 2.40 | 0.122 | 0.82 (0.64–1.05) | 0.119 |
| rs151235307 | 0.842 | 0.15 | 0.13 | 0.81 | 0.369 | 1.13 (0.85 | 0.384 |
| rs12752 | 0.523 | 0.28 | 0.31 | 2.51 | 0.113 | 0.83 (0.67 | 0.097 |
| rs62085661 | 0.396 | 0.28 | 0.32 | 2.79 | 0.095 | 0.82 (0.66 | 0.072 |
| rs12601492 | 0.925 | 0.44 | 0.42 | 0.44 | 0.505 | 1.06 (0.87 | 0.541 |
| rs9906439 | 0.103 | 0.24 | 0.21 | 1.16 | 0.282 | 1.12 (0.88 | 0.351 |
| rs3794742 | 0.170 | 0.47 | 0.49 | 0.65 | 0.421 | 0.91 (0.75 | 0.345 |
95%CI, 95% confidence interval; OR, odds ratio.
Pearson’s χ2 test for distributions of genotypes.
Logistic analysis in an additive model and adjusted for age, sex, and smoking status.
Association analyses between three SNPs and NSCLC risk in stage 2 and combined population.
| Stage 2 | Combined population | |||||||
|---|---|---|---|---|---|---|---|---|
| Case | Control | OR (95%CI) |
| Case | Control | OR (95%CI) |
| |
| rs13064999 | ||||||||
| GG | 513 | 583 | 1.00 | 632 | 770 | 1.00 | ||
| GA | 668 | 707 | 1.09 (0.97–1.28) | 0.313 | 839 | 931 | 1.11 (0.96–1.27) | 0.168 |
| AA | 245 | 197 | 1.40 (1.12–1.76) | 0.003 | 303 | 261 | 1.42 (1.16–1.73) | 0.001 |
| Dominant model | 1.16 (0.99–1.35) | 0.062 | 1.17 (1.03–1.34) | 0.020 | ||||
| Recessive model | 1.34 (1.09–1.65) | 0.006 | 1.34 (1.12–1.61) | 0.002 | ||||
| Additive model | 1.16 (1.04–1.29) | 0.006 | 1.17 (1.07–1.29) | 0.001 | ||||
| rs12752 | ||||||||
| TT | 136 | 137 | 1.00 | 166 | 180 | 1.00 | ||
| TC | 616 | 608 | 1.00 (0.77–1.30) | 0.989 | 748 | 819 | 0.99 (0.78–1.26) | 0.951 |
| CC | 712 | 714 | 0.99 (0.76–1.28) | 0.916 | 898 | 936 | 1.04 (0.82–1.31) | 0.750 |
| Dominant model | 1.01 (0.87–1.17) | 0.867 | 0.96 (0.84–1.09) | 0.507 | ||||
| Recessive model | 1.01 (0.78–1.30) | 0.947 | 0.98 (0.79–1.23) | 0.882 | ||||
| Additive model | 1.01 (0.90–1.13) | 0.875 | 0.97 (0.88–1.07) | 0.565 | ||||
| rs62085661 | ||||||||
| CC | 709 | 728 | 1.00 | 891 | 946 | 1.00 | ||
| CG | 604 | 634 | 0.98 (0.84–1.14) | 0.766 | 734 | 849 | 0.92 (0.80–1.06) | 0.233 |
| GG | 130 | 138 | 0.98 (0.75–1.27) | 0.860 | 160 | 181 | 0.93 (0.74–1.18) | 0.565 |
| Dominant model | 0.98 (0.84–1.13) | 0.753 | 0.92 (0.81–1.05) | 0.224 | ||||
| Recessive model | 0.99 (0.77–1.27) | 0.921 | 0.97 (0.77–1.22) | 0.791 | ||||
| Additive model | 0.98 (0.88–1.10) | 0.775 | 0.95 (0.86–1.05) | 0.292 | ||||
All the ORs and p-values were adjusted for sex, age, and smoking status.
ORs and 95% CIs calculations were conducted under assumption that variant alleles were risk alleles.
Subgroup analysis of SNP rs13064999 and NSCLC risk stratified by histology, smoking status, and sex.
| HT | HV | Dominant model | Recessive model | Additive model | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95%CI) |
| OR (95%CI) |
| OR (95%CI) |
| OR (95%CI) |
| OR (95%CI) |
| |
| Histologic type | ||||||||||
| Adenocarcinoma | 1.21 (1.03–1.42) | 0.024 | 1.52 (1.22–1.90) | <0.001 | 1.28 (1.09–1.49) | 0.002 | 1.37 (1.12–1.68) | 0.003 | 1.23 (1.10–1.38) | <0.001 |
| SCC | 0.97 (0.76–1.22) | 0.762 | 1.20 (0.87–1.66) | 0.268 | 1.02 (0.82–1.27) | 0.884 | 1.22 (0.91–1.64) | 0.180 | 1.07 (0.91–1.24) | 0.430 |
| Smoking status | ||||||||||
| Smoker | 1.02 (0.83–1.26) | 0.854 | 1.28 (0.94–1.72) | 0.113 | 1.08 (0.88–1.32) | 0.480 | 1.26 (0.96–1.66) | 0.099 | 1.10 (0.96–1.27) | 0.176 |
| Non-smoker | 1.17 (0.97–1.42) | 0.107 | 1.53 (1.18–2.00) | 0.002 | 1.25 (1.04–1.50) | 0.016 | 1.40 (1.10–1.79) | 0.006 | 1.22 (1.08–1.39) | 0.002 |
| Sex | ||||||||||
| Male | 1.03 (0.86–1.23) | 0.751 | 1.30 (1.02–1.67) | 0.037 | 1.09 (0.92–1.29) | 0.318 | 1.28 (1.02–1.61) | 0.032 | 1.12 (0.99–1.26) | 0.070 |
| Female | 1.23 (0.97–1.56) | 0.084 | 1.63 (1.17–2.26) | 0.004 | 1.31 (1.05–1.64) | 0.016 | 1.45 (1.07–1.96) | 0.016 | 1.27 (1.08–1.48) | 0.003 |
All the ORs and p-values were adjusted for sex, age, and smoking status.
HW, wild-type homozygote; HT, heterozygote; HV, variant homozygote.
ORs and 95% CIs calculations were conducted under assumption that variant alleles were risk alleles.
Squamous cell carcinoma.
Figure 1The variant rs13064999 influence gene transcription. (A) The bioinformatic analysis of rs13064999. Top, LD map of a total of 141 common SNPs in the 3q28 locus. Bottom, epigenetic tracks for the region surrounding SNP rs13064999 from ENCODE database. (B) The diagram of the recombinant plasmid used in luciferase assays. DNA fragments containing rs13064999[G/A] were cloned into pGL3-Promoter vector. (C, D) Relative reporter gene activity of the constructs containing rs13064999 G or A allele in A549 cells (C) and SK-MES-1 cells (D), respectively. Data were presented as mean ± SD from three independent experiments, each in triplicate. ***p < 0.001, **p < 0.01; p-values were calculated by a two-sided Student’s t-test.
Figure 2The variant rs13064999 showed an allele-specific binding to HP1γ. (A) EMSAs with biotin-labeled probes containing rs13064999-G or A allele in A549 and SK-MES-1 cell line. Lanes 1 and 6, biotin-labeled probe only; lanes 2 and 7, biotin-labeled probe and nuclear extracts; lanes 3–5 and 8–10, biotin-labeled probe, nuclear extracts plus 40× or 400× unlabeled competitor. Arrow indicates the allele-specific bands that interact with cells nuclear extracts. (B) Super-shift EMSA assays with the anti-HP1γ antibody in A549 and SK-MES-1 cells. Arrow indicates specific binding complexes to the A allele of rs13064999.